Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update
C Cutler, JH Antin - Current opinion in hematology, 2010 - journals.lww.com
C Cutler, JH Antin
Current opinion in hematology, 2010•journals.lww.comSirolimus should be considered for use in steroid-resistant acute and chronic GVHD.
Sirolimus appears promising as primary prophylaxis for GVHD prevention. Randomized
trials are currently being performed to determine whether sirolimus-based
immunosuppression is superior to traditional GVHD prophylaxis.
Sirolimus appears promising as primary prophylaxis for GVHD prevention. Randomized
trials are currently being performed to determine whether sirolimus-based
immunosuppression is superior to traditional GVHD prophylaxis.
Summary
Sirolimus should be considered for use in steroid-resistant acute and chronic GVHD. Sirolimus appears promising as primary prophylaxis for GVHD prevention. Randomized trials are currently being performed to determine whether sirolimus-based immunosuppression is superior to traditional GVHD prophylaxis.
Lippincott Williams & Wilkins